Navigation Links
Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
Date:5/19/2008

Adherence shows advantages over T-cell counts for monitoring HIV treatment

Information on how reliably people take their anti-HIV medicines can help identify those whose treatment will succeed or fail. Monitoring this information, which can be obtained directly from pharmacy records, works at least as well as performing blood tests that track the medicines effect on the immune system, according to research published in PLoS Medicine by Gregory Bisson, Jean Nachega and colleagues at the University of Pennsylvania, Johns Hopkins Bloomberg School of Public Health, and the University of Cape Town.

Adherence, or taking medications exactly as prescribed, has long been known to be a key factor in the success of HIV treatment. In developed countries, success has been defined using blood tests to measure how well medications suppress the AIDS virus. These so-called viral load tests are often difficult to provide in developing countries, so alternatives are used, including CD4 T-cell counts, which indicate how well the immune system is responding to treatment. However, falling CD4 counts tend to indicate treatment failure only after the fact, often at a point when the virus has developed resistance and the patients medications must be changed, typically to drugs that are more costly or difficult to take.

Working with an insurance plan that covers HIV treatment in 9 African countries, the researchers in this study calculated patient adherence from monthly claims for AIDS medicines actually dispensed by pharmacies, in proportion to the number of months that medicines were prescribed to the patient. Statistically comparing these adherence measures to CD4 test results in more than 1800 patients whose viral load results were available, they found that adherence was more accurate than CD4 counts in identifying individuals who went on to experience treatment failure over 6 months and 12 months of treatment.

These findings suggest that adherence assessments could be used for early identification of patients at high risk of treatment failure, averting its health impact and helping to prioritize limited viral load testing. Studies in other settings (such as public clinics where medication is provided without charge) are needed to confirm the general reliability of these findings.

These results do not change that fact that monitoring CD4 counts plays an important role in deciding when to begin HIV medications, or when to provide treatment to prevent conditions that occur at low CD4 counts. Nonetheless, according to the researchers, approaches to HIV treatment in resource-limited settings should include an adherence-based monitoring approach.

In an accompanying perspective article, David Bangsberg (University of California San Francisco, USA), who did not participate in the research, discusses the importance of proactive prevention rather than reactive response to HIV treatment failure.

Citation:Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, et al. (2008) Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on

antiretroviral therapy. PLoS Med 5(5): e109. doi:10.1371/journal.pmed.0050109

IN YOUR COVERAGE PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO THE PUBLISHED PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050109

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-05-bisson.pdf

CONTACTS:
Gregory P. Bisson
University of Pennsylvania School of Medicine
Center for Clinical Epidemiology and Biostatistics
Philadelphia, PA 19104-6021
United States of America
+1 215 573-5811
+1 215 573-5315
bisson@mail.med.upenn.edu

Related PLoS Medicine Perspective article:

Citation: Bangsberg DR (2008) A paradigm shift to prevent HIV drug resistance. PLoS Med 5(5): e11.doi:10.1371/journal.pmed.005011

IN YOUR COVERAGE PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO THE PUBLISHED PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050111

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-05-bangsberg.pdf

CONTACT:
David Bangsberg
University of California San Francisco
San Francisco General Hospital
Division of Infectious Diseases and the Positive Health Program
San Francisco, CA 92037
United States of America
+1 415-206-3462
db@epi-center.ucsf.edu


Role for vegf messenger RNA in promoting malignancy of human colon cancer cells

Vascular endothelial growth factor-A (VEGF) is a key regulator of tumor development, and a therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy is less effective than standard chemotherapy. Shigetada Teshima-Kondo and colleagues from the Institute of Health Bioscience, Tokushima, Japan investigated the role of vegf messenger (m)RNA in a line of cells from a colonic cancer. They showed that these cancer cells have a survival system that is regulated by vegf mRNA and hence that vegf mRNA and its protein may work together to promote the malignancy of tumor cells. Further work will need to be done to investigate how generalizable these findings are. The findings are discussed further in a Perspective article by Thomas Hughes and Pamela Jones, independent experts at the University of Leeds, UK, who were not involved in the study.

Citation: Masuda K, Teshima-Kondo S, Mukaijo M, Yamagishi N, Nishikawa Y, et al. (2008) A novel tumor-promoting function residing in the 59 non-coding region of vascular endothelial growth factor mRNA. PLoS Med 5(5): e94. doi:10.1371/journal.pmed.0050094

IN YOUR COVERAGE PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO THE PUBLISHED PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050094

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-05-teshima-kondo.pdf

CONTACT:
Shigetada Teshima-Kondo
University of Tokushima Graduate School
Institute of Health Bioscience
Department of Stress Science
3-18-15 Kuramoto-cho
Tokushima 770-8503
Japan
+81-88-633-9008
+81-88-633-9008 (fax)
kondoshi@basic.med.tokushima-u.ac.jp

Related PLoS Medicine Perspective article:

Citation: Hughes TA, Jones PF (2008) Regulatory RNAs: Have mRNA untranslated regions joined the party? PLoS Med 5(5): e110. doi:10.1371/journal.pmed.0050110

IN YOUR COVERAGE PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO THE PUBLISHED PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050110

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-05-hughes.pdf

CONTACT:
Thomas Hughes
University of Leeds
Leeds Institute of Molecular Medicine
Section of Molecular Gastroenterology
St. James's University Hospital
Leeds, LS9 7TF
United Kingdom
+44 113 3438624
+44 113 3438431 (fax)
t.hughes@leeds.ac.uk


'/>"/>

Contact: Andrew Hyde
press@plos.org
01-223-463-330
Public Library of Science
Source:Eurekalert

Related medicine news :

1. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
2. American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD
3. Mindray to Hold Conference Call to Discuss the Integration Plan and Closing of the Acquisition of Datascope Corp.s Patient Monitoring Business
4. Mindray Medical Completes Acquisition of Datascopes Patient Monitoring Business
5. Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life, Including Pregnancy
6. Mathematics simplifies sleep monitoring
7. Home Monitoring Program Improves Outcomes for Heart Patients
8. Oregon Supreme Court Rules in Favor of R.J. Reynolds Tobacco Company in Medical Monitoring Suit
9. Health Monitoring Systems Releases EpiCenter(TM)
10. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
11. New Patient Monitoring Devices Handle More Than Just Vital Signs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top ... and genders. And the need for advanced services is growing. , Project WE ... care program, in collaboration with their non-profit partners in their fight against cancer and ...
(Date:2/26/2017)... ... 2017 , ... NuevaCare, a leading home care agency based in San Mateo, ... is proud to announce an important upgrade to its geographic information pages, starting with ... to home, and by having city-specific pages, NuevaCare is answering that information need. , ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the ... in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on ... health management. , ODH will also have an exhibit booth where attendees may speak ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... 24, 2017 , ... An in-depth computational analysis of genetic variants implicated in ... eight genes that may explain why susceptibility to one of the disorders could place ... published today in the journal npj Schizophrenia. , “There is a wealth of ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Period October – December 2016 Revenues amounted to SEK ... million Result after tax amounted to SEK -16.3 (-6.5) million, ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... result amounted to SEK -39.5 (-29.5) million Result after tax ...
(Date:2/24/2017)... , Feb. 24, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the Cowen and ... the Boston Marriott Copley Place on Tuesday, March 7, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/24/2017)... Feb. 24, 2017  In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Tuesday, March 14, 2017 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology: